 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes METOPROLOL TARTRATE increase or [0m
[34mdecrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes METOPROLOL TARTRATE increase or [0m
[32mdecrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes METOPROLOL TARTRATE increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"METOPROLOL TARTRATE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: METOPROLOL TARTRATE: adverse_reactions_table: [0m[1;31m4[0m[31m%  [0m[1;31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m23.2[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> [0m
[31mBradycardia [0m[1;31m([0m[31mheart rate &lt;[0m[1;31m40[0m[31m beats/min[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m15.9[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m6.7[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m
[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> Second- or third-degree heart block  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m4.7[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m4[0m[31m. METOPROLOL TARTRATE: adverse_reactions_table: [0m[1;31m7[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> First-degree heart block [0m[1;31m([0m[31mP-R [0m
[31m&#x2265;[0m[1;31m0.26[0m[31m sec[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m5.3[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m1.9[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> [0m
[31mHeart failure  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m27.5[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m29[0m[31m. METOPROLOL TARTRATE: adverse_reactions_table: [0m[1;31m6[0m[31m%  [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: pharmacokinetics: Myocardial Infarction In a large [0m[1;31m([0m[1;31m1[0m[31m,[0m[1;31m395[0m[31m patients randomized[0m[1;31m)[0m[31m, double-blind, placebo-controlled clinical study, metoprolol was shown to reduce [0m[1;31m3[0m[31m-month [0m
[31mmortality by [0m[1;31m36[0m[31m% in patients with suspected or definite myocardial infarction. Patients were randomized and treated as soon as possible after their arrival in the hospital, once their clinical [0m
[31mcondition had stabilized and their hemodynamic status had been carefully evaluated. Subjects were ineligible if they had hypotension, bradycardia, peripheral signs of shock, and/or more than minimal [0m
[31mbasal rales as signs of congestive heart failure. Initial treatment consisted of intravenous followed by oral administration of metoprolol or placebo, given in a coronary care or comparable unit. Oral[0m
[31mmaintenance therapy with metoprolol or placebo was then continued for [0m[1;31m3[0m[31m months. After this double-blind period, all patients were given metoprolol and followed up to [0m[1;31m1[0m[31m year. METOPROLOL TARTRATE: [0m
[31mpharmacokinetics: The median delay from the onset of symptoms to the initiation of therapy was [0m[1;31m8[0m[31m hours in both the metoprolol- and placebo-treatment groups. Among patients treated with metoprolol, [0m
[31mthere were comparable reductions in [0m[1;31m3[0m[31m-month mortality for those treated early [0m[1;31m([0m[31mâ‰¤[0m[1;31m8[0m[31m hours[0m[1;31m)[0m[31m and those in whom treatment was started later. Significant reductions in the incidence of ventricular [0m
[31mfibrillation and in chest pain following initial intravenous therapy were also observed with metoprolol and were independent of the interval between onset of symptoms and initiation of therapy. In [0m
[31mthis study, patients treated with metoprolol received the drug both very early [0m[1;31m([0m[31mintra-venously[0m[1;31m)[0m[31m and during a subsequent [0m[1;31m3[0m[31m-month period, while placebo patients received no beta-blocker treatment for [0m
[31mthis period. The study thus was able to show a benefit from the overall metoprolol regimen but cannot separate the benefit of very early intravenous treatment from the benefit of later beta-blocker [0m
[31mtherapy. METOPROLOL TARTRATE: pharmacokinetics: Nonetheless, because the overall regimen showed a clear beneficial effect on survival without evidence of an early adverse effect on survival, one [0m
[31macceptable dosage regimen is the precise regimen used in the trial. Because the specific benefit of very early treatment remains to be defined however, it is also reasonable to administer the drug [0m
[31morally to patients at a later time as is recommended for certain other beta-blockers.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: precautions: PRECAUTIONS Risk of Anaphylactic Reactions While taking beta blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may [0m
[31mbe more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. Information [0m
[31mfor Patients Advise patients to take metoprolol regularly and continuously, as directed, with or immediately following meals. If a dose should be missed, the patient should take only the next [0m
[31mscheduled dose [0m[1;31m([0m[31mwithout doubling it[0m[1;31m)[0m[31m. Patients should not discontinue metoprolol without consulting the physician. METOPROLOL TARTRATE: precautions: Advise patients [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m to avoid operating automobiles [0m
[31mand machinery or engaging in other tasks requiring alertness until the patientâ€™s response to therapy with metoprolol has been determined; [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m to contact the physician if any difficulty in breathing [0m
[31moccurs; [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m to inform the physician or dentist before any type of surgery that he or she is taking metoprolol. Drug Interactions Catecholamine-depleting Drugs: Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., [0m
[31mreserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents or monoamine oxidase [0m[1;31m([0m[31mMAO[0m[1;31m)[0m[31m inhibitors. Observe patients treated with metoprolol plus a catecholamine depletor for evidence [0m
[31mof hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. METOPROLOL TARTRATE: precautions: In addition, possibly significant hypertension may theoretically [0m
[31moccur up to [0m[1;31m14[0m[31m days following discontinuation of the concomitant administration with an irreversible MAO inhibitor. Digitalis Glycosides and Beta-blockers: Both digitalis glycosides and beta-blockers [0m
[31mslow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. Monitor heart rate and PR interval. Calcium Channel Blockers: Concomitant administration[0m
[31mof a beta-adrenergic antagonist with a calcium channel blocker may produce an additive reduction in myocardial contractility because of negative chronotropic and inotropic effects. CYP2D6 Inhibitors: [0m
[31mPotent inhibitors of the CYP2D6 enzyme may increase the plasma concentration of metoprolol which would mimic the pharmacokinetics of CYP2D6 poor metabolizer [0m[1;31m([0m[31msee Pharmacokinetics section[0m[1;31m)[0m[31m. Increase in[0m
[31mplasma concentrations of metoprolol would decrease the cardioselectivity of metoprolol. METOPROLOL TARTRATE: drug_interactions: Known clinically significant potent inhibitors of CYP2D6 are [0m
[31mantidepressants such as fluvoxamine, fluoxetine, paroxetine, sertraline, bupropion, clomipramine, and desipramine; antipsychotics such as chlorpromazine, fluphenazine, haloperidol, and thioridazine; [0m
[31mantiarrhythmics such as quinidine or propafenone; antiretrovirals such as ritonavir; antihistamines such as diphenhydramine; antimalarials such as hydroxychloroquine or quinidine; antifungals such as [0m
[31mterbinafine. Hydralazine: Concomitant administration of hydralazine may inhibit presystemic metabolism of metoprolol leading to increased concentrations of metoprolol. METOPROLOL TARTRATE: [0m
[31mdrug_interactions: Alpha-adrenergic Agents: Antihypertensive effect of alpha-adrenergic blockers such as guanethidine, betanidine, reserpine, alpha-methyldopa or clonidine may be potentiated by [0m
[31mbeta-blockers including metoprolol. Beta-adrenergic blockers may also potentiate the postural hypotensive effect of the first dose of prazosin, probably by preventing reflex tachycardia. On the [0m
[31mcontrary, beta adrenergic blockers may also potentiate the hypertensive response to withdrawal of clonidine in patients receiving concomitant clonidine and beta-adrenergic blocker. If a patient is [0m
[31mtreated with clonidine and metoprolol concurrently, and clonidine treatment is to be discontinued, stop metoprolol several days before clonidine is withdrawn. Rebound hypertension that can follow [0m
[31mwithdrawal of clonidine may be increased in patients receiving concurrent beta-blocker treatment. METOPROLOL TARTRATE: drug_interactions: Drug Interactions Catecholamine-depleting Drugs: [0m
[31mCatecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents or monoamine oxidase [0m[1;31m([0m[31mMAO[0m[1;31m)[0m[31m inhibitors. Observe patients treated with metoprolol plus a [0m
[31mcatecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. In addition, possibly significant hypertension may theoretically [0m
[31moccur up to [0m[1;31m14[0m[31m days following discontinuation of the concomitant administration with an irreversible MAO inhibitor. Digitalis Glycosides and Beta-blockers: Both digitalis glycosides and beta-blockers [0m
[31mslow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. Monitor heart rate and PR interval. METOPROLOL TARTRATE: drug_interactions: Calcium [0m
[31mChannel Blockers: Concomitant administration of a beta-adrenergic antagonist with a calcium channel blocker may produce an additive reduction in myocardial contractility because of negative [0m
[31mchronotropic and inotropic effects. CYP2D6 Inhibitors: Potent inhibitors of the CYP2D6 enzyme may increase the plasma concentration of metoprolol which would mimic the pharmacokinetics of CYP2D6 poor [0m
[31mmetabolizer [0m[1;31m([0m[31msee Pharmacokinetics section[0m[1;31m)[0m[31m. Increase in plasma concentrations of metoprolol would decrease the cardioselectivity of metoprolol. METOPROLOL TARTRATE: precautions: Ergot Alkaloid: [0m
[31mConcomitant administration with beta-blockers may enhance the vasoconstrictive action of ergot alkaloids. Dipyridamole: In general, administration of a beta-blocker should be withheld before [0m
[31mdipyridamole testing, with careful monitoring of heart rate following the dipyridamole injection. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have been conducted [0m
[31mto evaluate carcinogenic potential. In a [0m[1;31m2[0m[31m-year study in rats at three oral dosage levels of up to [0m[1;31m800[0m[31m mg/kg per day, there was no increase in the development of spontaneously occurring benign or [0m
[31mmalignant neoplasms of any type. The only histologic changes that appeared to be drug related were an increased incidence of generally mild focal accumulation of foamy macrophages in pulmonary alveoli[0m
[31mand a slight increase in biliary hyperplasia. METOPROLOL TARTRATE: precautions: In a [0m[1;31m21[0m[31m-month study in Swiss albino mice at three oral dosage levels of up to [0m[1;31m750[0m[31m mg/kg per day, benign lung tumors [0m
[1;31m([0m[31msmall adenomas[0m[1;31m)[0m[31m occurred more frequently in female mice receiving the highest dose than in untreated control animals. There was no increase in malignant or total [0m[1;31m([0m[31mbenign plus malignant[0m[1;31m)[0m[31m lung tumors, [0m
[31mor in the overall incidence of tumors or malignant tumors. This [0m[1;31m21[0m[31m-month study was repeated in CD-[0m[1;31m1[0m[31m mice, and no statistically or biologically significant differences were observed between treated and[0m
[31mcontrol mice of either sex for any type of tumor. All mutagenicity tests performed [0m[1;31m([0m[31ma dominant lethal study in mice, chromosome studies in somatic cells, a Salmonella/mammalian-microsome mutagenicity [0m
[31mtest, and a nucleus anomaly test in somatic interphase nuclei[0m[1;31m)[0m[31m were negative. Reproduction toxicity studies in mice, rats and rabbits did not indicate teratogenic potential for metoprolol tartrate. [0m
[31mMETOPROLOL TARTRATE: precautions: Embryotoxicity and/or fetotoxicity in rats and rabbits were noted starting at doses of [0m[1;31m50[0m[31m mg/kg in rats and [0m[1;31m25[0m[31m mg/kg in rabbits, as demonstrated by increases in [0m
[31mpreimplantation loss, decreases in the number of viable fetuses per dose, and/or decreases in neonatal survival. High doses were associated with some maternal toxicity, and growth delay of the [0m
[31moffspring in utero , which was reflected in minimally lower weights at birth. The oral NOAELs for embryo-fetal development in mice, rats, and rabbits were considered to be [0m[1;31m25[0m[31m, [0m[1;31m200[0m[31m, and [0m[1;31m12.5[0m[31m mg/kg. [0m
[31mThis corresponds to dose levels that are approximately [0m[1;31m0.3[0m[31m, [0m[1;31m4[0m[31m, and [0m[1;31m0.5[0m[31m times, respectively, when based on surface area, the maximum human oral dose [0m[1;31m([0m[1;31m8[0m[31m mg/kg/day[0m[1;31m)[0m[31m of metoprolol tartrate. METOPROLOL [0m
[31mTARTRATE: precautions: Metoprolol tartrate has been associated with reversible adverse effects on spermatogenesis starting at oral dose levels of [0m[1;31m3.5[0m[31m mg/kg in rats [0m[1;31m([0m[31ma dose that is only [0m[1;31m0.1[0m[31m-times the [0m
[31mhuman dose, when based on surface area[0m[1;31m)[0m[31m, although other studies have shown no effect of metoprolol tartrate on reproductive performance in male rats. Pregnancy Category C Upon confirming the diagnosis[0m
[31mof pregnancy, women should immediately inform the doctor. Metoprolol has been shown to increase postimplantation loss and decrease neonatal survival in rats at doses up to [0m[1;31m11[0m[31m times the maximum daily [0m
[31mhuman dose of [0m[1;31m450[0m[31m mg, when based on surface area. Distribution studies in mice confirm exposure of the fetus when metoprolol is administered to the pregnant animal. These limited animal studies do not[0m
[31mindicate direct or indirect harmful effects with respect to teratogenicity [0m[1;31m([0m[31msee Carcinogenesis, Mutagenesis, Impairment of Fertility [0m[1;31m)[0m[31m. METOPROLOL TARTRATE: precautions: There are no adequate and [0m
[31mwell-controlled studies in pregnant women. The amount of data on the use of metoprolol in pregnant women is limited. The risk to the fetus/mother is unknown. Because animal reproduction studies are [0m
[31mnot always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing Mothers Metoprolol is excreted in breast milk in a very small quantity. An infant [0m
[31mconsuming [0m[1;31m1[0m[31m liter of breast milk daily would receive a dose of less than [0m[1;31m1[0m[31m mg of the drug. Fertility The effects of metoprolol on the fertility of human have not been studied. Metoprolol showed [0m
[31meffects on spermatogenesis in male rats at a therapeutic dose level, but had no effect on rates of conception at higher doses in animal fertility studies [0m[1;31m([0m[31msee Carcinogenesis, Mutagenesis, Impairment [0m
[31mof Fertility [0m[1;31m)[0m[31m. Pediatric Use Safety and effectiveness in pediatric patients have not been established. METOPROLOL TARTRATE: geriatric_use: Geriatric Use Clinical trials of metoprolol in hypertension [0m
[31mdid not include sufficient numbers of elderly patients to determine whether patients over [0m[1;31m65[0m[31m years of age differ from younger subjects in their response to metoprolol. Other reported clinical [0m
[31mexperience in elderly hypertensive patients has not identified any difference in response from younger patients. In worldwide clinical trials of metoprolol in myocardial infarction, where [0m
[31mapproximately [0m[1;31m478[0m[31m patients were over [0m[1;31m65[0m[31m years of age [0m[1;31m([0m[1;31m0[0m[31m over [0m[1;31m75[0m[31m years of age[0m[1;31m)[0m[31m, no age-related differences in safety and effectiveness were found. Other reported clinical experience in myocardial [0m
[31minfarction has not identified differences in response between the elderly and younger patients. However, greater sensitivity of some elderly individuals taking metoprolol cannot be categorically ruled[0m
[31mout. Therefore, in general, it is recommended that dosing proceed with caution in this population.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: adverse_reactions: Cardiovascular: In the randomized comparison of metoprolol and placebo described in the CLINICAL PHARMACOLOGY section, the following adverse reactions [0m
[31mwere reported: Metoprolol Placebo Hypotension [0m[1;31m([0m[31msystolic BP < [0m[1;31m90[0m[31m mmHg[0m[1;31m)[0m[31m [0m[1;31m27.4[0m[31m% [0m[1;31m23.2[0m[31m% Bradycardia [0m[1;31m([0m[31mheart rate <[0m[1;31m40[0m[31m beats/min[0m[1;31m)[0m[31m [0m[1;31m15.9[0m[31m% [0m[1;31m6.7[0m[31m% Second- or third-degree heart block [0m[1;31m4.7[0m[31m% [0m[1;31m4.7[0m[31m% First-degree heart [0m
[31mblock [0m[1;31m([0m[31mP-R â‰¥[0m[1;31m0.26[0m[31m sec[0m[1;31m)[0m[31m [0m[1;31m5.3[0m[31m% [0m[1;31m1.9[0m[31m% Heart failure [0m[1;31m27.5[0m[31m% [0m[1;31m29.6[0m[31m% Respiratory: Dyspnea of pulmonary origin has been reported in fewer than [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. Gastrointestinal: Nausea and abdominal pain have [0m
[31mbeen reported in fewer than [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. METOPROLOL TARTRATE: adverse_reactions: Dermatologic: Rash and worsened psoriasis have been reported, but a drug relationship is not clear. [0m
[31mMiscellaneous: Unstable diabetes and claudication have been reported, but a drug relationship is not clear. Potential Adverse Reactions A variety of adverse reactions not listed above have been [0m
[31mreported with other beta-adrenergic blocking agents and should be considered potential adverse reactions to metoprolol. Central Nervous System: Reversible mental depression progressing to catatonia; [0m
[31man acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on [0m
[31mneuropsychometrics. Cardiovascular: Intensification of AV block [0m[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. Hematologic: Agranulocytosis, nonthrombocytopenic purpura and thrombocytopenic purpura. METOPROLOL TARTRATE: [0m
[31madverse_reactions: Hypersensitive Reactions: Fever combined with aching and sore throat, laryngospasm and respiratory distress. Postmarketing Experience The following adverse reactions have been [0m
[31mreported during postapproval use of metoprolol: confusional state, an increase in blood triglycerides and a decrease in High Density Lipoprotein [0m[1;31m([0m[31mHDL[0m[1;31m)[0m[31m. Because these reports are from a population of [0m
[31muncertain size and are subject to confounding factors, it is not possible to reliably estimate their frequency.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: spl_set_id         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: product_ndc         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: brand_name         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: package_ndc         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: spl_id         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: dosage_and_administration: DOSAGE AND ADMINISTRATION Hypertension Individualized the dosage of metoprolol tartrate tablets. Metoprolol tartrate tablets should be taken [0m
[31mwith or immediately following meals. The usual initial dosage of metoprolol tartrate tablets is [0m[1;31m100[0m[31m mg daily in single or divided doses, whether used alone or added to a diuretic. Increase the dosage [0m
[31mat weekly [0m[1;31m([0m[31mor longer[0m[1;31m)[0m[31m intervals until optimum blood pressure reduction is achieved. In general, the maximum effect of any given dosage level will be apparent after [0m[1;31m1[0m[31m week of therapy. The effective [0m
[31mdosage range of metoprolol tartrate tablets is [0m[1;31m100[0m[31m to [0m[1;31m450[0m[31m mg per day. Dosages above [0m[1;31m450[0m[31m mg per day have not been studied. METOPROLOL TARTRATE: dosage_and_administration: While once-daily dosing is [0m
[31meffective and can maintain a reduction in blood pressure throughout the day, lower doses [0m[1;31m([0m[31mespecially [0m[1;31m100[0m[31m mg[0m[1;31m)[0m[31m may not maintain a full effect at the end of the [0m[1;31m24[0m[31m-hour period, and larger or more [0m
[31mfrequent daily doses may be required. This can be evaluated by measuring blood pressure near the end of the dosing interval to determine whether satisfactory control is being maintained throughout the[0m
[31mday. Beta [0m[1;31m1[0m[31m selectivity diminishes as the dose of metoprolol is increased. Angina Pectoris The dosage of metoprolol tartrate tablets should be individualized. Metoprolol tartrate tablets should be [0m
[31mtaken with or immediately following meals. The usual initial dosage of metoprolol tartrate tablets is [0m[1;31m100[0m[31m mg daily, given in two divided doses. Gradually increase the dosage at weekly intervals until [0m
[31moptimum clinical response has been obtained or there is pronounced slowing of the heart rate. METOPROLOL TARTRATE: dosage_and_administration: The effective dosage range of metoprolol tartrate tablets [0m
[31mis [0m[1;31m100[0m[31m to [0m[1;31m400[0m[31m mg per day. Dosages above [0m[1;31m400[0m[31m mg per day have not been studied. If treatment is to be discontinued, gradually decrease the dosage over a period of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m weeks [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. [0m
[31mMyocardial Infarction Early Treatment During the early phase of definite or suspected acute myocardial infarction, initiate treatment with metoprolol tartrate tablets as soon as possible after the [0m
[31mpatient's arrival in the hospital. Such treatment should be initiated in a coronary care or similar unit immediately after the patientâ€™s hemodynamic condition has stabilized. Begin treatment in this [0m
[31mearly phase with the intravenous administration of three bolus injections of [0m[1;31m5[0m[31m mg of metoprolol tartrate each; give the injections at approximately [0m[1;31m2[0m[31m-minute intervals. During the intravenous [0m
[31madministration of metoprolol, monitor blood pressure, heart rate, and electrocardiogram.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: product_type         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: pediatric_use: Pediatric Use Safety and effectiveness in pediatric patients have not been established.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"METOPROLOL TARTRATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does METOPROLOL TARTRATE increase or decrease the [0m
[31mrisk of gastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes METOPROLOL TARTRATE increase or [0m
[32mdecrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes METOPROLOL TARTRATE increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"METOPROLOL TARTRATE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: METOPROLOL TARTRATE: adverse_reactions_table: [0m[1;31m4[0m[31m%  [0m[1;31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m23.2[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> [0m
[31mBradycardia [0m[1;31m([0m[31mheart rate &lt;[0m[1;31m40[0m[31m beats/min[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m15.9[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m6.7[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m
[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> Second- or third-degree heart block  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m4.7[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m4[0m[31m. METOPROLOL TARTRATE: adverse_reactions_table: [0m[1;31m7[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> First-degree heart block [0m[1;31m([0m[31mP-R [0m
[31m&#x2265;[0m[1;31m0.26[0m[31m sec[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m5.3[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m1.9[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> [0m
[31mHeart failure  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m27.5[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m29[0m[31m. METOPROLOL TARTRATE: adverse_reactions_table: [0m[1;31m6[0m[31m%  [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: pharmacokinetics: Myocardial Infarction In a large [0m[1;31m([0m[1;31m1[0m[31m,[0m[1;31m395[0m[31m patients randomized[0m[1;31m)[0m[31m, double-blind, placebo-controlled clinical study, metoprolol was shown to reduce [0m[1;31m3[0m[31m-month [0m
[31mmortality by [0m[1;31m36[0m[31m% in patients with suspected or definite myocardial infarction. Patients were randomized and treated as soon as possible after their arrival in the hospital, once their clinical [0m
[31mcondition had stabilized and their hemodynamic status had been carefully evaluated. Subjects were ineligible if they had hypotension, bradycardia, peripheral signs of shock, and/or more than minimal [0m
[31mbasal rales as signs of congestive heart failure. Initial treatment consisted of intravenous followed by oral administration of metoprolol or placebo, given in a coronary care or comparable unit. Oral[0m
[31mmaintenance therapy with metoprolol or placebo was then continued for [0m[1;31m3[0m[31m months. After this double-blind period, all patients were given metoprolol and followed up to [0m[1;31m1[0m[31m year. METOPROLOL TARTRATE: [0m
[31mpharmacokinetics: The median delay from the onset of symptoms to the initiation of therapy was [0m[1;31m8[0m[31m hours in both the metoprolol- and placebo-treatment groups. Among patients treated with metoprolol, [0m
[31mthere were comparable reductions in [0m[1;31m3[0m[31m-month mortality for those treated early [0m[1;31m([0m[31mâ‰¤[0m[1;31m8[0m[31m hours[0m[1;31m)[0m[31m and those in whom treatment was started later. Significant reductions in the incidence of ventricular [0m
[31mfibrillation and in chest pain following initial intravenous therapy were also observed with metoprolol and were independent of the interval between onset of symptoms and initiation of therapy. In [0m
[31mthis study, patients treated with metoprolol received the drug both very early [0m[1;31m([0m[31mintra-venously[0m[1;31m)[0m[31m and during a subsequent [0m[1;31m3[0m[31m-month period, while placebo patients received no beta-blocker treatment for [0m
[31mthis period. The study thus was able to show a benefit from the overall metoprolol regimen but cannot separate the benefit of very early intravenous treatment from the benefit of later beta-blocker [0m
[31mtherapy. METOPROLOL TARTRATE: pharmacokinetics: Nonetheless, because the overall regimen showed a clear beneficial effect on survival without evidence of an early adverse effect on survival, one [0m
[31macceptable dosage regimen is the precise regimen used in the trial. Because the specific benefit of very early treatment remains to be defined however, it is also reasonable to administer the drug [0m
[31morally to patients at a later time as is recommended for certain other beta-blockers.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: precautions: PRECAUTIONS Risk of Anaphylactic Reactions While taking beta blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may [0m
[31mbe more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. Information [0m
[31mfor Patients Advise patients to take metoprolol regularly and continuously, as directed, with or immediately following meals. If a dose should be missed, the patient should take only the next [0m
[31mscheduled dose [0m[1;31m([0m[31mwithout doubling it[0m[1;31m)[0m[31m. Patients should not discontinue metoprolol without consulting the physician. METOPROLOL TARTRATE: precautions: Advise patients [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m to avoid operating automobiles [0m
[31mand machinery or engaging in other tasks requiring alertness until the patientâ€™s response to therapy with metoprolol has been determined; [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m to contact the physician if any difficulty in breathing [0m
[31moccurs; [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m to inform the physician or dentist before any type of surgery that he or she is taking metoprolol. Drug Interactions Catecholamine-depleting Drugs: Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., [0m
[31mreserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents or monoamine oxidase [0m[1;31m([0m[31mMAO[0m[1;31m)[0m[31m inhibitors. Observe patients treated with metoprolol plus a catecholamine depletor for evidence [0m
[31mof hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. METOPROLOL TARTRATE: precautions: In addition, possibly significant hypertension may theoretically [0m
[31moccur up to [0m[1;31m14[0m[31m days following discontinuation of the concomitant administration with an irreversible MAO inhibitor. Digitalis Glycosides and Beta-blockers: Both digitalis glycosides and beta-blockers [0m
[31mslow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. Monitor heart rate and PR interval. Calcium Channel Blockers: Concomitant administration[0m
[31mof a beta-adrenergic antagonist with a calcium channel blocker may produce an additive reduction in myocardial contractility because of negative chronotropic and inotropic effects. CYP2D6 Inhibitors: [0m
[31mPotent inhibitors of the CYP2D6 enzyme may increase the plasma concentration of metoprolol which would mimic the pharmacokinetics of CYP2D6 poor metabolizer [0m[1;31m([0m[31msee Pharmacokinetics section[0m[1;31m)[0m[31m. Increase in[0m
[31mplasma concentrations of metoprolol would decrease the cardioselectivity of metoprolol. METOPROLOL TARTRATE: drug_interactions: Known clinically significant potent inhibitors of CYP2D6 are [0m
[31mantidepressants such as fluvoxamine, fluoxetine, paroxetine, sertraline, bupropion, clomipramine, and desipramine; antipsychotics such as chlorpromazine, fluphenazine, haloperidol, and thioridazine; [0m
[31mantiarrhythmics such as quinidine or propafenone; antiretrovirals such as ritonavir; antihistamines such as diphenhydramine; antimalarials such as hydroxychloroquine or quinidine; antifungals such as [0m
[31mterbinafine. Hydralazine: Concomitant administration of hydralazine may inhibit presystemic metabolism of metoprolol leading to increased concentrations of metoprolol. METOPROLOL TARTRATE: [0m
[31mdrug_interactions: Alpha-adrenergic Agents: Antihypertensive effect of alpha-adrenergic blockers such as guanethidine, betanidine, reserpine, alpha-methyldopa or clonidine may be potentiated by [0m
[31mbeta-blockers including metoprolol. Beta-adrenergic blockers may also potentiate the postural hypotensive effect of the first dose of prazosin, probably by preventing reflex tachycardia. On the [0m
[31mcontrary, beta adrenergic blockers may also potentiate the hypertensive response to withdrawal of clonidine in patients receiving concomitant clonidine and beta-adrenergic blocker. If a patient is [0m
[31mtreated with clonidine and metoprolol concurrently, and clonidine treatment is to be discontinued, stop metoprolol several days before clonidine is withdrawn. Rebound hypertension that can follow [0m
[31mwithdrawal of clonidine may be increased in patients receiving concurrent beta-blocker treatment. METOPROLOL TARTRATE: drug_interactions: Drug Interactions Catecholamine-depleting Drugs: [0m
[31mCatecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents or monoamine oxidase [0m[1;31m([0m[31mMAO[0m[1;31m)[0m[31m inhibitors. Observe patients treated with metoprolol plus a [0m
[31mcatecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. In addition, possibly significant hypertension may theoretically [0m
[31moccur up to [0m[1;31m14[0m[31m days following discontinuation of the concomitant administration with an irreversible MAO inhibitor. Digitalis Glycosides and Beta-blockers: Both digitalis glycosides and beta-blockers [0m
[31mslow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. Monitor heart rate and PR interval. METOPROLOL TARTRATE: drug_interactions: Calcium [0m
[31mChannel Blockers: Concomitant administration of a beta-adrenergic antagonist with a calcium channel blocker may produce an additive reduction in myocardial contractility because of negative [0m
[31mchronotropic and inotropic effects. CYP2D6 Inhibitors: Potent inhibitors of the CYP2D6 enzyme may increase the plasma concentration of metoprolol which would mimic the pharmacokinetics of CYP2D6 poor [0m
[31mmetabolizer [0m[1;31m([0m[31msee Pharmacokinetics section[0m[1;31m)[0m[31m. Increase in plasma concentrations of metoprolol would decrease the cardioselectivity of metoprolol. METOPROLOL TARTRATE: precautions: Ergot Alkaloid: [0m
[31mConcomitant administration with beta-blockers may enhance the vasoconstrictive action of ergot alkaloids. Dipyridamole: In general, administration of a beta-blocker should be withheld before [0m
[31mdipyridamole testing, with careful monitoring of heart rate following the dipyridamole injection. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have been conducted [0m
[31mto evaluate carcinogenic potential. In a [0m[1;31m2[0m[31m-year study in rats at three oral dosage levels of up to [0m[1;31m800[0m[31m mg/kg per day, there was no increase in the development of spontaneously occurring benign or [0m
[31mmalignant neoplasms of any type. The only histologic changes that appeared to be drug related were an increased incidence of generally mild focal accumulation of foamy macrophages in pulmonary alveoli[0m
[31mand a slight increase in biliary hyperplasia. METOPROLOL TARTRATE: precautions: In a [0m[1;31m21[0m[31m-month study in Swiss albino mice at three oral dosage levels of up to [0m[1;31m750[0m[31m mg/kg per day, benign lung tumors [0m
[1;31m([0m[31msmall adenomas[0m[1;31m)[0m[31m occurred more frequently in female mice receiving the highest dose than in untreated control animals. There was no increase in malignant or total [0m[1;31m([0m[31mbenign plus malignant[0m[1;31m)[0m[31m lung tumors, [0m
[31mor in the overall incidence of tumors or malignant tumors. This [0m[1;31m21[0m[31m-month study was repeated in CD-[0m[1;31m1[0m[31m mice, and no statistically or biologically significant differences were observed between treated and[0m
[31mcontrol mice of either sex for any type of tumor. All mutagenicity tests performed [0m[1;31m([0m[31ma dominant lethal study in mice, chromosome studies in somatic cells, a Salmonella/mammalian-microsome mutagenicity [0m
[31mtest, and a nucleus anomaly test in somatic interphase nuclei[0m[1;31m)[0m[31m were negative. Reproduction toxicity studies in mice, rats and rabbits did not indicate teratogenic potential for metoprolol tartrate. [0m
[31mMETOPROLOL TARTRATE: precautions: Embryotoxicity and/or fetotoxicity in rats and rabbits were noted starting at doses of [0m[1;31m50[0m[31m mg/kg in rats and [0m[1;31m25[0m[31m mg/kg in rabbits, as demonstrated by increases in [0m
[31mpreimplantation loss, decreases in the number of viable fetuses per dose, and/or decreases in neonatal survival. High doses were associated with some maternal toxicity, and growth delay of the [0m
[31moffspring in utero , which was reflected in minimally lower weights at birth. The oral NOAELs for embryo-fetal development in mice, rats, and rabbits were considered to be [0m[1;31m25[0m[31m, [0m[1;31m200[0m[31m, and [0m[1;31m12.5[0m[31m mg/kg. [0m
[31mThis corresponds to dose levels that are approximately [0m[1;31m0.3[0m[31m, [0m[1;31m4[0m[31m, and [0m[1;31m0.5[0m[31m times, respectively, when based on surface area, the maximum human oral dose [0m[1;31m([0m[1;31m8[0m[31m mg/kg/day[0m[1;31m)[0m[31m of metoprolol tartrate. METOPROLOL [0m
[31mTARTRATE: precautions: Metoprolol tartrate has been associated with reversible adverse effects on spermatogenesis starting at oral dose levels of [0m[1;31m3.5[0m[31m mg/kg in rats [0m[1;31m([0m[31ma dose that is only [0m[1;31m0.1[0m[31m-times the [0m
[31mhuman dose, when based on surface area[0m[1;31m)[0m[31m, although other studies have shown no effect of metoprolol tartrate on reproductive performance in male rats. Pregnancy Category C Upon confirming the diagnosis[0m
[31mof pregnancy, women should immediately inform the doctor. Metoprolol has been shown to increase postimplantation loss and decrease neonatal survival in rats at doses up to [0m[1;31m11[0m[31m times the maximum daily [0m
[31mhuman dose of [0m[1;31m450[0m[31m mg, when based on surface area. Distribution studies in mice confirm exposure of the fetus when metoprolol is administered to the pregnant animal. These limited animal studies do not[0m
[31mindicate direct or indirect harmful effects with respect to teratogenicity [0m[1;31m([0m[31msee Carcinogenesis, Mutagenesis, Impairment of Fertility [0m[1;31m)[0m[31m. METOPROLOL TARTRATE: precautions: There are no adequate and [0m
[31mwell-controlled studies in pregnant women. The amount of data on the use of metoprolol in pregnant women is limited. The risk to the fetus/mother is unknown. Because animal reproduction studies are [0m
[31mnot always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing Mothers Metoprolol is excreted in breast milk in a very small quantity. An infant [0m
[31mconsuming [0m[1;31m1[0m[31m liter of breast milk daily would receive a dose of less than [0m[1;31m1[0m[31m mg of the drug. Fertility The effects of metoprolol on the fertility of human have not been studied. Metoprolol showed [0m
[31meffects on spermatogenesis in male rats at a therapeutic dose level, but had no effect on rates of conception at higher doses in animal fertility studies [0m[1;31m([0m[31msee Carcinogenesis, Mutagenesis, Impairment [0m
[31mof Fertility [0m[1;31m)[0m[31m. Pediatric Use Safety and effectiveness in pediatric patients have not been established. METOPROLOL TARTRATE: geriatric_use: Geriatric Use Clinical trials of metoprolol in hypertension [0m
[31mdid not include sufficient numbers of elderly patients to determine whether patients over [0m[1;31m65[0m[31m years of age differ from younger subjects in their response to metoprolol. Other reported clinical [0m
[31mexperience in elderly hypertensive patients has not identified any difference in response from younger patients. In worldwide clinical trials of metoprolol in myocardial infarction, where [0m
[31mapproximately [0m[1;31m478[0m[31m patients were over [0m[1;31m65[0m[31m years of age [0m[1;31m([0m[1;31m0[0m[31m over [0m[1;31m75[0m[31m years of age[0m[1;31m)[0m[31m, no age-related differences in safety and effectiveness were found. Other reported clinical experience in myocardial [0m
[31minfarction has not identified differences in response between the elderly and younger patients. However, greater sensitivity of some elderly individuals taking metoprolol cannot be categorically ruled[0m
[31mout. Therefore, in general, it is recommended that dosing proceed with caution in this population.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: adverse_reactions: Cardiovascular: In the randomized comparison of metoprolol and placebo described in the CLINICAL PHARMACOLOGY section, the following adverse reactions [0m
[31mwere reported: Metoprolol Placebo Hypotension [0m[1;31m([0m[31msystolic BP < [0m[1;31m90[0m[31m mmHg[0m[1;31m)[0m[31m [0m[1;31m27.4[0m[31m% [0m[1;31m23.2[0m[31m% Bradycardia [0m[1;31m([0m[31mheart rate <[0m[1;31m40[0m[31m beats/min[0m[1;31m)[0m[31m [0m[1;31m15.9[0m[31m% [0m[1;31m6.7[0m[31m% Second- or third-degree heart block [0m[1;31m4.7[0m[31m% [0m[1;31m4.7[0m[31m% First-degree heart [0m
[31mblock [0m[1;31m([0m[31mP-R â‰¥[0m[1;31m0.26[0m[31m sec[0m[1;31m)[0m[31m [0m[1;31m5.3[0m[31m% [0m[1;31m1.9[0m[31m% Heart failure [0m[1;31m27.5[0m[31m% [0m[1;31m29.6[0m[31m% Respiratory: Dyspnea of pulmonary origin has been reported in fewer than [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. Gastrointestinal: Nausea and abdominal pain have [0m
[31mbeen reported in fewer than [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. METOPROLOL TARTRATE: adverse_reactions: Dermatologic: Rash and worsened psoriasis have been reported, but a drug relationship is not clear. [0m
[31mMiscellaneous: Unstable diabetes and claudication have been reported, but a drug relationship is not clear. Potential Adverse Reactions A variety of adverse reactions not listed above have been [0m
[31mreported with other beta-adrenergic blocking agents and should be considered potential adverse reactions to metoprolol. Central Nervous System: Reversible mental depression progressing to catatonia; [0m
[31man acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on [0m
[31mneuropsychometrics. Cardiovascular: Intensification of AV block [0m[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. Hematologic: Agranulocytosis, nonthrombocytopenic purpura and thrombocytopenic purpura. METOPROLOL TARTRATE: [0m
[31madverse_reactions: Hypersensitive Reactions: Fever combined with aching and sore throat, laryngospasm and respiratory distress. Postmarketing Experience The following adverse reactions have been [0m
[31mreported during postapproval use of metoprolol: confusional state, an increase in blood triglycerides and a decrease in High Density Lipoprotein [0m[1;31m([0m[31mHDL[0m[1;31m)[0m[31m. Because these reports are from a population of [0m
[31muncertain size and are subject to confounding factors, it is not possible to reliably estimate their frequency.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: spl_set_id         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: product_ndc         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: brand_name         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: package_ndc         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: spl_id         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: dosage_and_administration: DOSAGE AND ADMINISTRATION Hypertension Individualized the dosage of metoprolol tartrate tablets. Metoprolol tartrate tablets should be taken [0m
[31mwith or immediately following meals. The usual initial dosage of metoprolol tartrate tablets is [0m[1;31m100[0m[31m mg daily in single or divided doses, whether used alone or added to a diuretic. Increase the dosage [0m
[31mat weekly [0m[1;31m([0m[31mor longer[0m[1;31m)[0m[31m intervals until optimum blood pressure reduction is achieved. In general, the maximum effect of any given dosage level will be apparent after [0m[1;31m1[0m[31m week of therapy. The effective [0m
[31mdosage range of metoprolol tartrate tablets is [0m[1;31m100[0m[31m to [0m[1;31m450[0m[31m mg per day. Dosages above [0m[1;31m450[0m[31m mg per day have not been studied. METOPROLOL TARTRATE: dosage_and_administration: While once-daily dosing is [0m
[31meffective and can maintain a reduction in blood pressure throughout the day, lower doses [0m[1;31m([0m[31mespecially [0m[1;31m100[0m[31m mg[0m[1;31m)[0m[31m may not maintain a full effect at the end of the [0m[1;31m24[0m[31m-hour period, and larger or more [0m
[31mfrequent daily doses may be required. This can be evaluated by measuring blood pressure near the end of the dosing interval to determine whether satisfactory control is being maintained throughout the[0m
[31mday. Beta [0m[1;31m1[0m[31m selectivity diminishes as the dose of metoprolol is increased. Angina Pectoris The dosage of metoprolol tartrate tablets should be individualized. Metoprolol tartrate tablets should be [0m
[31mtaken with or immediately following meals. The usual initial dosage of metoprolol tartrate tablets is [0m[1;31m100[0m[31m mg daily, given in two divided doses. Gradually increase the dosage at weekly intervals until [0m
[31moptimum clinical response has been obtained or there is pronounced slowing of the heart rate. METOPROLOL TARTRATE: dosage_and_administration: The effective dosage range of metoprolol tartrate tablets [0m
[31mis [0m[1;31m100[0m[31m to [0m[1;31m400[0m[31m mg per day. Dosages above [0m[1;31m400[0m[31m mg per day have not been studied. If treatment is to be discontinued, gradually decrease the dosage over a period of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m weeks [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. [0m
[31mMyocardial Infarction Early Treatment During the early phase of definite or suspected acute myocardial infarction, initiate treatment with metoprolol tartrate tablets as soon as possible after the [0m
[31mpatient's arrival in the hospital. Such treatment should be initiated in a coronary care or similar unit immediately after the patientâ€™s hemodynamic condition has stabilized. Begin treatment in this [0m
[31mearly phase with the intravenous administration of three bolus injections of [0m[1;31m5[0m[31m mg of metoprolol tartrate each; give the injections at approximately [0m[1;31m2[0m[31m-minute intervals. During the intravenous [0m
[31madministration of metoprolol, monitor blood pressure, heart rate, and electrocardiogram.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: product_type         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: pediatric_use: Pediatric Use Safety and effectiveness in pediatric patients have not been established.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes METOPROLOL TARTRATE increase or [0m
[32mdecrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes METOPROLOL TARTRATE increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"METOPROLOL TARTRATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does METOPROLOL TARTRATE increase or decrease the [0m
[31mrisk of gastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes METOPROLOL TARTRATE increase or [0m
[32mdecrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes METOPROLOL TARTRATE increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"METOPROLOL TARTRATE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: METOPROLOL TARTRATE: adverse_reactions_table: [0m[1;31m4[0m[31m%  [0m[1;31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m23.2[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> [0m
[31mBradycardia [0m[1;31m([0m[31mheart rate &lt;[0m[1;31m40[0m[31m beats/min[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m15.9[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m6.7[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m
[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> Second- or third-degree heart block  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m4.7[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m4[0m[31m. METOPROLOL TARTRATE: adverse_reactions_table: [0m[1;31m7[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> First-degree heart block [0m[1;31m([0m[31mP-R [0m
[31m&#x2265;[0m[1;31m0.26[0m[31m sec[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m5.3[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m1.9[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> [0m
[31mHeart failure  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m27.5[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m29[0m[31m. METOPROLOL TARTRATE: adverse_reactions_table: [0m[1;31m6[0m[31m%  [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: pharmacokinetics: Myocardial Infarction In a large [0m[1;31m([0m[1;31m1[0m[31m,[0m[1;31m395[0m[31m patients randomized[0m[1;31m)[0m[31m, double-blind, placebo-controlled clinical study, metoprolol was shown to reduce [0m[1;31m3[0m[31m-month [0m
[31mmortality by [0m[1;31m36[0m[31m% in patients with suspected or definite myocardial infarction. Patients were randomized and treated as soon as possible after their arrival in the hospital, once their clinical [0m
[31mcondition had stabilized and their hemodynamic status had been carefully evaluated. Subjects were ineligible if they had hypotension, bradycardia, peripheral signs of shock, and/or more than minimal [0m
[31mbasal rales as signs of congestive heart failure. Initial treatment consisted of intravenous followed by oral administration of metoprolol or placebo, given in a coronary care or comparable unit. Oral[0m
[31mmaintenance therapy with metoprolol or placebo was then continued for [0m[1;31m3[0m[31m months. After this double-blind period, all patients were given metoprolol and followed up to [0m[1;31m1[0m[31m year. METOPROLOL TARTRATE: [0m
[31mpharmacokinetics: The median delay from the onset of symptoms to the initiation of therapy was [0m[1;31m8[0m[31m hours in both the metoprolol- and placebo-treatment groups. Among patients treated with metoprolol, [0m
[31mthere were comparable reductions in [0m[1;31m3[0m[31m-month mortality for those treated early [0m[1;31m([0m[31mâ‰¤[0m[1;31m8[0m[31m hours[0m[1;31m)[0m[31m and those in whom treatment was started later. Significant reductions in the incidence of ventricular [0m
[31mfibrillation and in chest pain following initial intravenous therapy were also observed with metoprolol and were independent of the interval between onset of symptoms and initiation of therapy. In [0m
[31mthis study, patients treated with metoprolol received the drug both very early [0m[1;31m([0m[31mintra-venously[0m[1;31m)[0m[31m and during a subsequent [0m[1;31m3[0m[31m-month period, while placebo patients received no beta-blocker treatment for [0m
[31mthis period. The study thus was able to show a benefit from the overall metoprolol regimen but cannot separate the benefit of very early intravenous treatment from the benefit of later beta-blocker [0m
[31mtherapy. METOPROLOL TARTRATE: pharmacokinetics: Nonetheless, because the overall regimen showed a clear beneficial effect on survival without evidence of an early adverse effect on survival, one [0m
[31macceptable dosage regimen is the precise regimen used in the trial. Because the specific benefit of very early treatment remains to be defined however, it is also reasonable to administer the drug [0m
[31morally to patients at a later time as is recommended for certain other beta-blockers.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: precautions: PRECAUTIONS Risk of Anaphylactic Reactions While taking beta blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may [0m
[31mbe more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. Information [0m
[31mfor Patients Advise patients to take metoprolol regularly and continuously, as directed, with or immediately following meals. If a dose should be missed, the patient should take only the next [0m
[31mscheduled dose [0m[1;31m([0m[31mwithout doubling it[0m[1;31m)[0m[31m. Patients should not discontinue metoprolol without consulting the physician. METOPROLOL TARTRATE: precautions: Advise patients [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m to avoid operating automobiles [0m
[31mand machinery or engaging in other tasks requiring alertness until the patientâ€™s response to therapy with metoprolol has been determined; [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m to contact the physician if any difficulty in breathing [0m
[31moccurs; [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m to inform the physician or dentist before any type of surgery that he or she is taking metoprolol. Drug Interactions Catecholamine-depleting Drugs: Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., [0m
[31mreserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents or monoamine oxidase [0m[1;31m([0m[31mMAO[0m[1;31m)[0m[31m inhibitors. Observe patients treated with metoprolol plus a catecholamine depletor for evidence [0m
[31mof hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. METOPROLOL TARTRATE: precautions: In addition, possibly significant hypertension may theoretically [0m
[31moccur up to [0m[1;31m14[0m[31m days following discontinuation of the concomitant administration with an irreversible MAO inhibitor. Digitalis Glycosides and Beta-blockers: Both digitalis glycosides and beta-blockers [0m
[31mslow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. Monitor heart rate and PR interval. Calcium Channel Blockers: Concomitant administration[0m
[31mof a beta-adrenergic antagonist with a calcium channel blocker may produce an additive reduction in myocardial contractility because of negative chronotropic and inotropic effects. CYP2D6 Inhibitors: [0m
[31mPotent inhibitors of the CYP2D6 enzyme may increase the plasma concentration of metoprolol which would mimic the pharmacokinetics of CYP2D6 poor metabolizer [0m[1;31m([0m[31msee Pharmacokinetics section[0m[1;31m)[0m[31m. Increase in[0m
[31mplasma concentrations of metoprolol would decrease the cardioselectivity of metoprolol. METOPROLOL TARTRATE: drug_interactions: Known clinically significant potent inhibitors of CYP2D6 are [0m
[31mantidepressants such as fluvoxamine, fluoxetine, paroxetine, sertraline, bupropion, clomipramine, and desipramine; antipsychotics such as chlorpromazine, fluphenazine, haloperidol, and thioridazine; [0m
[31mantiarrhythmics such as quinidine or propafenone; antiretrovirals such as ritonavir; antihistamines such as diphenhydramine; antimalarials such as hydroxychloroquine or quinidine; antifungals such as [0m
[31mterbinafine. Hydralazine: Concomitant administration of hydralazine may inhibit presystemic metabolism of metoprolol leading to increased concentrations of metoprolol. METOPROLOL TARTRATE: [0m
[31mdrug_interactions: Alpha-adrenergic Agents: Antihypertensive effect of alpha-adrenergic blockers such as guanethidine, betanidine, reserpine, alpha-methyldopa or clonidine may be potentiated by [0m
[31mbeta-blockers including metoprolol. Beta-adrenergic blockers may also potentiate the postural hypotensive effect of the first dose of prazosin, probably by preventing reflex tachycardia. On the [0m
[31mcontrary, beta adrenergic blockers may also potentiate the hypertensive response to withdrawal of clonidine in patients receiving concomitant clonidine and beta-adrenergic blocker. If a patient is [0m
[31mtreated with clonidine and metoprolol concurrently, and clonidine treatment is to be discontinued, stop metoprolol several days before clonidine is withdrawn. Rebound hypertension that can follow [0m
[31mwithdrawal of clonidine may be increased in patients receiving concurrent beta-blocker treatment. METOPROLOL TARTRATE: drug_interactions: Drug Interactions Catecholamine-depleting Drugs: [0m
[31mCatecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents or monoamine oxidase [0m[1;31m([0m[31mMAO[0m[1;31m)[0m[31m inhibitors. Observe patients treated with metoprolol plus a [0m
[31mcatecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. In addition, possibly significant hypertension may theoretically [0m
[31moccur up to [0m[1;31m14[0m[31m days following discontinuation of the concomitant administration with an irreversible MAO inhibitor. Digitalis Glycosides and Beta-blockers: Both digitalis glycosides and beta-blockers [0m
[31mslow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. Monitor heart rate and PR interval. METOPROLOL TARTRATE: drug_interactions: Calcium [0m
[31mChannel Blockers: Concomitant administration of a beta-adrenergic antagonist with a calcium channel blocker may produce an additive reduction in myocardial contractility because of negative [0m
[31mchronotropic and inotropic effects. CYP2D6 Inhibitors: Potent inhibitors of the CYP2D6 enzyme may increase the plasma concentration of metoprolol which would mimic the pharmacokinetics of CYP2D6 poor [0m
[31mmetabolizer [0m[1;31m([0m[31msee Pharmacokinetics section[0m[1;31m)[0m[31m. Increase in plasma concentrations of metoprolol would decrease the cardioselectivity of metoprolol. METOPROLOL TARTRATE: precautions: Ergot Alkaloid: [0m
[31mConcomitant administration with beta-blockers may enhance the vasoconstrictive action of ergot alkaloids. Dipyridamole: In general, administration of a beta-blocker should be withheld before [0m
[31mdipyridamole testing, with careful monitoring of heart rate following the dipyridamole injection. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have been conducted [0m
[31mto evaluate carcinogenic potential. In a [0m[1;31m2[0m[31m-year study in rats at three oral dosage levels of up to [0m[1;31m800[0m[31m mg/kg per day, there was no increase in the development of spontaneously occurring benign or [0m
[31mmalignant neoplasms of any type. The only histologic changes that appeared to be drug related were an increased incidence of generally mild focal accumulation of foamy macrophages in pulmonary alveoli[0m
[31mand a slight increase in biliary hyperplasia. METOPROLOL TARTRATE: precautions: In a [0m[1;31m21[0m[31m-month study in Swiss albino mice at three oral dosage levels of up to [0m[1;31m750[0m[31m mg/kg per day, benign lung tumors [0m
[1;31m([0m[31msmall adenomas[0m[1;31m)[0m[31m occurred more frequently in female mice receiving the highest dose than in untreated control animals. There was no increase in malignant or total [0m[1;31m([0m[31mbenign plus malignant[0m[1;31m)[0m[31m lung tumors, [0m
[31mor in the overall incidence of tumors or malignant tumors. This [0m[1;31m21[0m[31m-month study was repeated in CD-[0m[1;31m1[0m[31m mice, and no statistically or biologically significant differences were observed between treated and[0m
[31mcontrol mice of either sex for any type of tumor. All mutagenicity tests performed [0m[1;31m([0m[31ma dominant lethal study in mice, chromosome studies in somatic cells, a Salmonella/mammalian-microsome mutagenicity [0m
[31mtest, and a nucleus anomaly test in somatic interphase nuclei[0m[1;31m)[0m[31m were negative. Reproduction toxicity studies in mice, rats and rabbits did not indicate teratogenic potential for metoprolol tartrate. [0m
[31mMETOPROLOL TARTRATE: precautions: Embryotoxicity and/or fetotoxicity in rats and rabbits were noted starting at doses of [0m[1;31m50[0m[31m mg/kg in rats and [0m[1;31m25[0m[31m mg/kg in rabbits, as demonstrated by increases in [0m
[31mpreimplantation loss, decreases in the number of viable fetuses per dose, and/or decreases in neonatal survival. High doses were associated with some maternal toxicity, and growth delay of the [0m
[31moffspring in utero , which was reflected in minimally lower weights at birth. The oral NOAELs for embryo-fetal development in mice, rats, and rabbits were considered to be [0m[1;31m25[0m[31m, [0m[1;31m200[0m[31m, and [0m[1;31m12.5[0m[31m mg/kg. [0m
[31mThis corresponds to dose levels that are approximately [0m[1;31m0.3[0m[31m, [0m[1;31m4[0m[31m, and [0m[1;31m0.5[0m[31m times, respectively, when based on surface area, the maximum human oral dose [0m[1;31m([0m[1;31m8[0m[31m mg/kg/day[0m[1;31m)[0m[31m of metoprolol tartrate. METOPROLOL [0m
[31mTARTRATE: precautions: Metoprolol tartrate has been associated with reversible adverse effects on spermatogenesis starting at oral dose levels of [0m[1;31m3.5[0m[31m mg/kg in rats [0m[1;31m([0m[31ma dose that is only [0m[1;31m0.1[0m[31m-times the [0m
[31mhuman dose, when based on surface area[0m[1;31m)[0m[31m, although other studies have shown no effect of metoprolol tartrate on reproductive performance in male rats. Pregnancy Category C Upon confirming the diagnosis[0m
[31mof pregnancy, women should immediately inform the doctor. Metoprolol has been shown to increase postimplantation loss and decrease neonatal survival in rats at doses up to [0m[1;31m11[0m[31m times the maximum daily [0m
[31mhuman dose of [0m[1;31m450[0m[31m mg, when based on surface area. Distribution studies in mice confirm exposure of the fetus when metoprolol is administered to the pregnant animal. These limited animal studies do not[0m
[31mindicate direct or indirect harmful effects with respect to teratogenicity [0m[1;31m([0m[31msee Carcinogenesis, Mutagenesis, Impairment of Fertility [0m[1;31m)[0m[31m. METOPROLOL TARTRATE: precautions: There are no adequate and [0m
[31mwell-controlled studies in pregnant women. The amount of data on the use of metoprolol in pregnant women is limited. The risk to the fetus/mother is unknown. Because animal reproduction studies are [0m
[31mnot always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing Mothers Metoprolol is excreted in breast milk in a very small quantity. An infant [0m
[31mconsuming [0m[1;31m1[0m[31m liter of breast milk daily would receive a dose of less than [0m[1;31m1[0m[31m mg of the drug. Fertility The effects of metoprolol on the fertility of human have not been studied. Metoprolol showed [0m
[31meffects on spermatogenesis in male rats at a therapeutic dose level, but had no effect on rates of conception at higher doses in animal fertility studies [0m[1;31m([0m[31msee Carcinogenesis, Mutagenesis, Impairment [0m
[31mof Fertility [0m[1;31m)[0m[31m. Pediatric Use Safety and effectiveness in pediatric patients have not been established. METOPROLOL TARTRATE: geriatric_use: Geriatric Use Clinical trials of metoprolol in hypertension [0m
[31mdid not include sufficient numbers of elderly patients to determine whether patients over [0m[1;31m65[0m[31m years of age differ from younger subjects in their response to metoprolol. Other reported clinical [0m
[31mexperience in elderly hypertensive patients has not identified any difference in response from younger patients. In worldwide clinical trials of metoprolol in myocardial infarction, where [0m
[31mapproximately [0m[1;31m478[0m[31m patients were over [0m[1;31m65[0m[31m years of age [0m[1;31m([0m[1;31m0[0m[31m over [0m[1;31m75[0m[31m years of age[0m[1;31m)[0m[31m, no age-related differences in safety and effectiveness were found. Other reported clinical experience in myocardial [0m
[31minfarction has not identified differences in response between the elderly and younger patients. However, greater sensitivity of some elderly individuals taking metoprolol cannot be categorically ruled[0m
[31mout. Therefore, in general, it is recommended that dosing proceed with caution in this population.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: adverse_reactions: Cardiovascular: In the randomized comparison of metoprolol and placebo described in the CLINICAL PHARMACOLOGY section, the following adverse reactions [0m
[31mwere reported: Metoprolol Placebo Hypotension [0m[1;31m([0m[31msystolic BP < [0m[1;31m90[0m[31m mmHg[0m[1;31m)[0m[31m [0m[1;31m27.4[0m[31m% [0m[1;31m23.2[0m[31m% Bradycardia [0m[1;31m([0m[31mheart rate <[0m[1;31m40[0m[31m beats/min[0m[1;31m)[0m[31m [0m[1;31m15.9[0m[31m% [0m[1;31m6.7[0m[31m% Second- or third-degree heart block [0m[1;31m4.7[0m[31m% [0m[1;31m4.7[0m[31m% First-degree heart [0m
[31mblock [0m[1;31m([0m[31mP-R â‰¥[0m[1;31m0.26[0m[31m sec[0m[1;31m)[0m[31m [0m[1;31m5.3[0m[31m% [0m[1;31m1.9[0m[31m% Heart failure [0m[1;31m27.5[0m[31m% [0m[1;31m29.6[0m[31m% Respiratory: Dyspnea of pulmonary origin has been reported in fewer than [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. Gastrointestinal: Nausea and abdominal pain have [0m
[31mbeen reported in fewer than [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. METOPROLOL TARTRATE: adverse_reactions: Dermatologic: Rash and worsened psoriasis have been reported, but a drug relationship is not clear. [0m
[31mMiscellaneous: Unstable diabetes and claudication have been reported, but a drug relationship is not clear. Potential Adverse Reactions A variety of adverse reactions not listed above have been [0m
[31mreported with other beta-adrenergic blocking agents and should be considered potential adverse reactions to metoprolol. Central Nervous System: Reversible mental depression progressing to catatonia; [0m
[31man acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on [0m
[31mneuropsychometrics. Cardiovascular: Intensification of AV block [0m[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. Hematologic: Agranulocytosis, nonthrombocytopenic purpura and thrombocytopenic purpura. METOPROLOL TARTRATE: [0m
[31madverse_reactions: Hypersensitive Reactions: Fever combined with aching and sore throat, laryngospasm and respiratory distress. Postmarketing Experience The following adverse reactions have been [0m
[31mreported during postapproval use of metoprolol: confusional state, an increase in blood triglycerides and a decrease in High Density Lipoprotein [0m[1;31m([0m[31mHDL[0m[1;31m)[0m[31m. Because these reports are from a population of [0m
[31muncertain size and are subject to confounding factors, it is not possible to reliably estimate their frequency.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: spl_set_id         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: product_ndc         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: brand_name         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: package_ndc         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: spl_id         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: dosage_and_administration: DOSAGE AND ADMINISTRATION Hypertension Individualized the dosage of metoprolol tartrate tablets. Metoprolol tartrate tablets should be taken [0m
[31mwith or immediately following meals. The usual initial dosage of metoprolol tartrate tablets is [0m[1;31m100[0m[31m mg daily in single or divided doses, whether used alone or added to a diuretic. Increase the dosage [0m
[31mat weekly [0m[1;31m([0m[31mor longer[0m[1;31m)[0m[31m intervals until optimum blood pressure reduction is achieved. In general, the maximum effect of any given dosage level will be apparent after [0m[1;31m1[0m[31m week of therapy. The effective [0m
[31mdosage range of metoprolol tartrate tablets is [0m[1;31m100[0m[31m to [0m[1;31m450[0m[31m mg per day. Dosages above [0m[1;31m450[0m[31m mg per day have not been studied. METOPROLOL TARTRATE: dosage_and_administration: While once-daily dosing is [0m
[31meffective and can maintain a reduction in blood pressure throughout the day, lower doses [0m[1;31m([0m[31mespecially [0m[1;31m100[0m[31m mg[0m[1;31m)[0m[31m may not maintain a full effect at the end of the [0m[1;31m24[0m[31m-hour period, and larger or more [0m
[31mfrequent daily doses may be required. This can be evaluated by measuring blood pressure near the end of the dosing interval to determine whether satisfactory control is being maintained throughout the[0m
[31mday. Beta [0m[1;31m1[0m[31m selectivity diminishes as the dose of metoprolol is increased. Angina Pectoris The dosage of metoprolol tartrate tablets should be individualized. Metoprolol tartrate tablets should be [0m
[31mtaken with or immediately following meals. The usual initial dosage of metoprolol tartrate tablets is [0m[1;31m100[0m[31m mg daily, given in two divided doses. Gradually increase the dosage at weekly intervals until [0m
[31moptimum clinical response has been obtained or there is pronounced slowing of the heart rate. METOPROLOL TARTRATE: dosage_and_administration: The effective dosage range of metoprolol tartrate tablets [0m
[31mis [0m[1;31m100[0m[31m to [0m[1;31m400[0m[31m mg per day. Dosages above [0m[1;31m400[0m[31m mg per day have not been studied. If treatment is to be discontinued, gradually decrease the dosage over a period of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m weeks [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. [0m
[31mMyocardial Infarction Early Treatment During the early phase of definite or suspected acute myocardial infarction, initiate treatment with metoprolol tartrate tablets as soon as possible after the [0m
[31mpatient's arrival in the hospital. Such treatment should be initiated in a coronary care or similar unit immediately after the patientâ€™s hemodynamic condition has stabilized. Begin treatment in this [0m
[31mearly phase with the intravenous administration of three bolus injections of [0m[1;31m5[0m[31m mg of metoprolol tartrate each; give the injections at approximately [0m[1;31m2[0m[31m-minute intervals. During the intravenous [0m
[31madministration of metoprolol, monitor blood pressure, heart rate, and electrocardiogram.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: product_type         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: pediatric_use: Pediatric Use Safety and effectiveness in pediatric patients have not been established.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label data does not specify whether METOPROLOL TARTRATE increases or decreases the risk of gastrointestinal ulcer hospitalization. Therefore, I cannot provide a definitive answer to this [0m
[32mquestion. It is important to note that the absence of information in the FDA label data does not necessarily mean that there is no effect; it may simply indicate that the effect has not been [0m
[32msufficiently studied or reported to warrant inclusion in the label.[0m
